Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
INTRODUCTION: Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is widely used as an option treatment for pain relief among osteoarthritis patients as it acts as a lubricant in the joints. Tualang Honey Formulation (THF...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Malaysian Orthopaedic Association
2024
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/116542/13/116542_%20Tualang%20honey%20formulation%20as%20potential%20Osteoarthritis.pdf http://irep.iium.edu.my/116542/ https://www.morthoj.org/supplements/moa-2024/Poster/Ortho-Research/ER05.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | INTRODUCTION:
Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is widely used as an option treatment for pain relief among osteoarthritis patients as it acts as a lubricant in the joints. Tualang Honey Formulation (THF), a patented (patent no. MY179303-A) viscosupplement, is being investigated as a potential treatment for OA. This study aimed to evaluate the biocompatibility of THF by assessing cell viability upon exposure.
MATERIALS & METHODS:
A dose-response cytotoxicity of THF was evaluated in V79-4 cells. The THF was dissolved in a two-times complete growth medium at the concentration of 50% v/v. A serial 2-fold dilution was carried out using a complete growth medium prior to exposure towards cells. Cells were exposed to serially diluted Tualang Honey Formulation (THF) concentrations (1.56% to 50% v/v) for 24 hours. The cytotoxicity was determined by accessing the cell viability through the reduction of tetrazolium salts (MTT). Cell viability was obtained by dividing the mean optical density (OD) values of the THF with the mean OD of negative control and multiplied by 100.
RESULTS AND DISCUSSIONS:
V79-4 cells were used to study the cytotoxicity of THF. As shown in Table 1, the viability of the cell treated with the THF was more than 73% in all concentrations. Figure 1 shows the cell viability of THF at all concentrations. The outcomes of this study showed there was no toxicity for THF even at higher concentrations, which demonstrated that THF can be used safely and applied in OA as a potential viscosupplement.
CONCLUSION:
The present study revealed that THF did not demonstrate a cytotoxic effect when exposed to the cell. This outcome shows that THF is biocompatible and is a potential candidate for osteoarthritis treatment in future. |
|---|